N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide

Pramiracetam was discovered by scientists at Parke-Davis at that time a division of Warner-Lambert in the late 1970s patents expired in 1996. Warner-Lambert conducted clinical trials in Alzheimers Disease and abandoned that indication after Phase II trials showed mixed results it then began to develop it as an orphan drug as an adjunct to electroconvulsive therapy for major depressive disorder in part to take advantage of the administrative exclusivity provided by the orphan status. It licensed European rights to Menarini which continued developing it for dementias and in 1991 it licensed US and other non-European rights to Cambridge Neuroscience Inc (CNI) which pursued the ECT indication as well as a use in restoring cognitive function after stroke or traumatic brain injury. CNI obtained the orphan designation for the ECT use from the FDA in 1991 which was later withdrawn when CNI abandoned the drug.

For R&D use onlynot for drug household or other uses.

Pramiracetam is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. It is marketed by Menarini under the brand name Pramistar as a treatment for memory and attention deficits in aging people with neurodegenerative and vascular dementias in Italy and some Eastern European countries.